Pum Tech (688389.SH): Company's product receives IVDR CE certification

Gelonghui, July 8 — Pumantech (688389.SH) announced that 29 of its electrochemiluminescence reagent products and one hemoglobin chromatography column have received IVDR CE certification issued by TÜV SÜD, a European Union Notified Body. The new EU In Vitro Diagnostic Medical Devices Regulation (IVDR, EU 2017/746) has replaced the previous EU In Vitro Diagnostic Medical Devices Directive (IVDD, 98/79/EC) to regulate in vitro diagnostic medical devices in the EU market. To date, the company has cumulatively obtained IVDR CE certification for 82 electrochemiluminescence reagent products. According to the EU

Gelonghui FinanceJul 8 20:30

Pumen Technology (688389.SH) announced that its actual controller plans to increase holdings of the company's shares by an amount between RMB 10 million and RMB 30 million.

Pumeng Technology (688389.SH) announced that Liu Xiancheng, the company's controlling shareholder, actual controller, and chairman of the board, intends to purchase shares of the company through centralized bidding transactions via the Shanghai Stock Exchange trading system, using his own funds, within six months from the date of disclosure of the share purchase plan. The proposed amount for the share purchase is no less than RMB 10 million (inclusive) and no more than RMB 30 million (inclusive).

Zhitong FinanceJun 30 18:52

Express News | Pum Tech: Obtained Medical Device Registration Certificate for Glycated Hemoglobin Assay Kit

BreakingsJun 18 16:08

Primedeas Biotech Co., Ltd. (SHA: 688389): Zhai Roumei Resigns as Securities Affairs Representative

Gelonghui, June 9 — Primedeq Technology Co., Ltd. (SHA: 688389) announced that the company's board of directors recently received a written resignation letter from Ms. Zhai Roumei, the company's securities affairs representative. Ms. Zhai Roumei has applied to resign from her position as securities affairs representative for personal reasons. The resignation takes effect upon delivery to the company's board of directors. Following her resignation, Ms. Zhai will no longer hold any position at the company, and her departure will not affect the normal operation of the company's relevant activities.

Gelonghui FinanceJun 9 16:51

Pumen Technology (688389) 2025 Annual Report and 2026 Q1 Report Commentary: Short-Term Earnings Under Pressure; Platform Strategy and Overseas Expansion Continue to Advance

Item: The company released its 2025 annual report and 2026 first-quarter report. Full-year 2025 revenue was RMB 1.038 billion (-9.60%), attributable net profit was RMB 184 million (-46.66%), and non-recurring-item-adjusted attributable net profit was RMB 163 million.

Huachuang SecuritiesMay 26 16:02

Primed Biotech (688389): Domestic business faces short-term pressure, while overseas markets show strong growth.

The company's performance declined in the short term. For the full year of 2025, the company reported revenue of RMB 1.038 billion (a year-over-year decrease of 9.60%, unless otherwise stated), net profit attributable to shareholders of RMB 184 million (down 46.66%), and net profit attributable to shareholders excluding non-recurring gains and losses of RMB 163 million (

Donghai SecuritiesMay 26 00:00